[Skip to Content]
[Skip to Content Landing]
July 4, 1990

The Role of Data Audits in Detecting Scientific Misconduct-Reply

JAMA. 1990;264(1):38. doi:10.1001/jama.1990.03450010039026

In Reply.—  Wyllie et al1 believed that the bioavailability of generic primidone was deficient. They may well have been right about the bioavailability: I do not pretend to know. This issue is addressed in the response above from Nightingale and colleagues. As Dr Conomy indicates, I did not address the issue of bioavailability in my editorial,2 which was certainly not written to "acknowledge or address" all the points they made in their article, far less to pronounce on their correctness. The editorial question that the article by Wyllie et al posed, and the question I addressed, was not the correctness of the data, but the provision of all relevant data. The reason that Wyllie et al looked into the question of bioavailability of primidone in the first place was, I believe, because the patient's seizures increased in frequency. If, shortly afterward (and well before submittal of the